Women are often underrepresented in HIV clinical trials, but they appear to prefer finding out about trials by means of peer-to-peer communication, according to new analysis.
Women are often underrepresented in HIV clinical trials, making it difficult to decipher the relevance of findings and whether they are applicable to all, but they appear to prefer finding out about trials by means of peer-to-peer communication, according to new analysis.
Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) researchers Sara Looby, PhD, and Markella Zanni, MD, uncovered women’s preferred methods for learning about a clinical study were peer-to-peer communication (52% of those questioned), provider communication (46%), and video-based communication (39%). Women were most likely to take part to gain information (63%) and to help others (47%).
Coinciding with National Women and Girls HIV/AIDS Awareness Day in the U.S., which was March 10, they have published their data in the Taylor & Francis journal HIV Clinical Trials. The article shows how an evidence-based campaign, Follow YOUR Heart, is empowering older women with HIV to participate in a large-scale clinical trial, called REPRIEVE, which is aimed at preventing cardiovascular disease.
“Feedback from our community sample of women offered valuable perspectives on methods to help educate and engage women with HIV on research participation, making our Follow YOUR Heart campaign truly patient-centered,” the authors noted.
Looby is assistant professor of Medicine at HMS, a principal investigator in the Program of Nutritional Metabolism, and a nurse scientist at the Yvonne L. Munn Center for Nursing Research at MGH. Her research is focused on cardiometabolic and bone health among individuals aging with HIV, particularly women. She also has conducted studies related to menopause symptoms, and cardiovascular disease in relation to reproductive aging.
Zanni is a physician in the MGH Neuroendocrine Clinical Center, a faculty member in the Neuroendocrine Unit at MGH, and an assistant professor of medicine at HMS. She is a clinical researcher in the MGH Program in Nutritional Metabolism and she studies metabolic and cardiovascular complications of inflammation.
Philip Ward is the European Editor for Applied Clinical Trials
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.